Suggestions
Tim Sweeney
CEO @ Inflammatix, Inc. | Helping solve sepsis
Tim Sweeney is a seasoned professional in the healthcare industry, known for his role as the co-founder and CEO of Inflammatix, a groundbreaking molecular diagnostics startup.
With a strong background in medicine, data science, and machine learning, he is dedicated to leveraging technology to revolutionize clinical diagnostics, particularly in the field of acute infections and critical illnesses.
Tim's educational achievements include a Postdoctoral MS in Biomedical Informatics from Stanford University School of Medicine, an MD, PhD from Duke University School of Medicine, and a combination of undergraduate degrees in Biology, Chemistry, and Biological Chemistry from the University of Chicago.
Apart from his leadership at Inflammatix, he is actively involved in mentoring and investing in early-stage startups in the biotech and medtech sectors, demonstrating his commitment to advancing innovation in healthcare.
Tim Sweeney has held various key roles in organizations, including serving on the Steering Committee at the Sepsis Innovation Council, contributing as a StartX Mentor and Neighborhood Lead, and offering support as an Angel Investor in startups like Amenities Health, Teach-Now, and Axial Fund.
His prior experience encompasses research roles at the Stanford University Institute of Immunity, Transplantation, and Infection, as well as a residency in General Surgery at Stanford University School of Medicine.
With a primary focus on developing rapid, point-of-care tests to accurately identify infections and improve patient outcomes, Tim aims to combat antibiotic resistance and make a significant impact on global healthcare challenges.
Highlights
Check out my upcoming presentation on host-response #diagnostics in infections and #sepsis at the Next Generation Dx Summit this August. Comment below or reach out if you want to connect onsite! #NGDx
The extraordinary burden of culture-negative #sepsis on full display in a recent article in Critical Care Medicine from the Society of Critical Care Medicine.
Tetsu et al show that across 147,061 community-acquired #sepsis patients, only 14% had positive blood cultures, and another 14% had positive cultures from another site. Meaning 72% had no positive cultures at all!
Culture, ID, and AST are critical when we can get them, but more needs to be done to get actionable information to physicians in the vast majority of cases. #Host-response profiling could be the answer - quick decisions on whether an infection is present, what type if so, and how sick the patient is. Better #diagnostics will lead to better outcomes!
Link to the study: https://lnkd.in/gcWzxytW
